Compare Mesoblast Limited (MESO) vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. (ZTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $20.15 (market cap $14.70B). The key difference: ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. is far larger — about 8.4× Mesoblast Limited's market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays a 3.47% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | ZTO | |
|---|---|---|
Market Cap | $1.75B | $14.70B |
Volume | 239,027 | 1,484,646 |
Sector | Health | Industrials |
52-Week High | $20.96 | $25.88 |
52-Week Low | $13.19 | $18.50 |
Typical Hold Time | 15 Days | — |
Enterprise Value | $1.83B | $13.32B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.
ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.
Read more on ZTO →
